AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 302 min read$CLYM

Brennan Aoife sold $407K of CLYM

Brennan Aoife (President and CEO) sold 30,902 shares of Climb Bio, Inc. (CLYM) at $13.17 ($0.41M total) on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brennan Aoife
Published Jun 30, 2026, 11:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 11:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CLYM
Neutral
medium confidence
Mentioned
$CLYM
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLYMNeutralLow
01

Why it matters

The newest concrete fact is the reported open-market sale of 30,902 shares at $13.1700/share, totaling about $406,979, executed 2026-06-29 and filed 2026-06-30 under a 10b5-1 plan.

02

Market read

Insider selling by a top executive can influence sentiment, but the 10b5-1 framing makes this more of a monitoring datapoint than a tradable fundamental catalyst.

03

What to watch

The filing does not disclose any new operational, clinical, or financial developments—so traders should avoid over-weighting it versus upcoming company-specific catalysts.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed 2026-06-30 for a sale executed 2026-06-29

Background

The article is an SEC Form 4 insider transaction disclosure for Climb Bio, Inc. (CLYM) by its President and CEO, Brennan Aoife.

Company-level read

Ticker impact

$CLYMNeutralMedium confidence
Context

Climb Bio CEO Brennan Aoife filed a Form 4 selling 30,902 shares at $13.17 on 2026-06-29 under a 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The disclosure is a scheduled open-market sale by the CEO with a stated 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

No sector-level read-across; this is company-specific insider transaction reporting.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity/compensation mechanics rather than bearish expectations.

Key entities

  • issuer
    Climb Bio, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Brennan Aoife

    President and CEO; reported open-market sale under a 10b5-1 plan.

  • trading mechanism
    10b5-1 plan

    Pre-arranged plan that typically reduces inference about near-term insider expectations.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CLYM insider trading history →

Related articles

OCT 23
$CLYMMedAI 8/10

Climb Bio Reports CLYM116 Phase 1 Data Supporting 12-Week Dosing

Climb Bio reported Phase 1 results for CLYM116, showing sustained APRIL suppression through 12 weeks and reductions in IgA and Gd-IgA1. A single dose of at least 480 mg suppressed free APRIL by 90% or more, supporting a potential every-12-week regimen. The antibody was generally well tolerated. Phase 2 trial is enrolling, with initial data expected in the first half of 2027, and a Phase 3 trial is expected to begin in 2027, pending regulatory feedback.

tradingview.com1 min
OCT 23
$CLYMHighAI 8/10

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026 >90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 1

SEC EDGAR 8-K2 min
OCT 23
$CLYMHighAI 8/10

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026

Climb Bio (CLYM) and Mabworks presented Phase 1 data for CLYM116/MIL116 at ASN Kidney Week 2026, showing 90% free APRIL suppression and 70% Gd-IgA1 reduction. The drug has a 33-day half-life, supports Q12W dosing, and is generally well-tolerated. NAVIGATE-2 Phase 2 trial is enrolling, with initial data expected in 2027, and a global Phase 3 trial is planned for 2027.

markets.businessinsider.com3 min
OCT 20
$CLYMHigh

Why is Climb Bio stock surging today?

Climb Bio Inc. (CLYM) rose 10.9% after Deutsche Bank initiated coverage with a Buy rating and $28.00 target, citing its autoimmune drug pipeline. The bank noted recent valuation compression reflected sector-wide selloff, not company-specific issues. Multiple analysts maintain bullish ratings with targets up to $40, citing positive clinical data. Broader market gains and biotech sector stabilization also supported the move.

investing.com2 min
OCT 20
$CLYMHigh

Deutsche Bank starts Climb Bio at Buy, citing compelling autoimmune pipeline

Climb Bio (CLYM) shares rose 10% after Deutsche Bank initiated coverage with a Buy rating and $28 price target, citing its autoimmune pipeline and attractive valuation. Analyst David Hoang highlighted CLYM116 as a key growth driver and noted upcoming clinical updates as catalysts. The firm sees significant commercial potential in the company's pipeline, including budoprutug for multiple B cell-mediated disorders.

investing.com2 min